Gene-knocked out chimeric antigen receptor (CAR) T cells: Tuning up for the next generation cancer immunotherapy

Mirzaei, H.R. and Pourghadamyari, H. and Rahmati, M. and Mohammadi, A. and Nahand, J.S. and Rezaei, A. and Mirzaei, H. and Hadjati, J. (2018) Gene-knocked out chimeric antigen receptor (CAR) T cells: Tuning up for the next generation cancer immunotherapy. Cancer Letters, 423. pp. 95-104.

Full text not available from this repository.
Official URL:


Recently clinical trials utilizing genetically engineered T cells expressing a chimeric antigen receptor (CAR) that is half monoclonal antibody and half T-cell receptor have demonstrated remarkable response in patients with advanced cancers like relapsed or refractory acute lymphoblastic leukemia (ALL) and lymphoma. Moreover, emerging chimeric genome editing tools such as zinc-finger nucleases (ZNFs), transcription activator-like effector nucleases (TALENs) and clustered regulatory interspaced short palindromic repeat (CRISPR)/Cas composed of sequence-specific DNA binding module(s) linked to a non-specific DNA cleavage domain have made possible to dramatically expand the ability to manipulate cells aim to treat and/or study a wide range of diseases including cancer. Here, we will discuss how joint application of these two chimeras will help us to manipulate CAR T cells aiming to enhance the efficacy of CAR T cell therapy in preclinical and clinical settings. © 2018 Elsevier B.V.

Item Type: Article
Additional Information: cited By 0
Uncontrolled Keywords: chimeric antigen receptor, apoptosis; cancer immunotherapy; cell survival; cell therapy; chimera; clinical effectiveness; clinical study; gene knockout; gene targeting; human; immunosuppressive treatment; nonhuman; preclinical study; priority journal; Short Survey; T lymphocyte; tumor microenvironment
Subjects: QZ Pathology
Depositing User: eprints admin
Date Deposited: 23 Dec 2018 06:39
Last Modified: 18 Aug 2019 04:14

Actions (login required)

View Item View Item